The most researched dual recovery peptide stack in biohacking communities worldwide. Two compounds, two non-overlapping mechanisms, one protocol. ≥98% purity on both. COA included. Ships worldwide.
The wolverine stack peptide is a dual research combination of BPC-157 and TB-500 — two of the most extensively studied recovery-focused peptides in preclinical science. The name comes from the Marvel character's legendary regenerative healing ability, and the parallel to the published research on these two compounds is what made the name stick in biohacking and research communities worldwide.
What makes the wolverine stack scientifically compelling isn't just what each compound does individually — it's the fact that they operate through completely non-overlapping mechanisms. BPC-157 works locally, driving angiogenesis and vascular repair at the site of injury via the VEGFR2/Akt/eNOS signaling axis. TB-500 works systemically, mobilizing fibroblasts and keratinocytes throughout the body by regulating G-actin sequestration. One builds the repair infrastructure. The other sends the repair cells. Together they cover both phases of tissue regeneration in a way that neither compound can achieve alone.
At VantyxLabs, both BPC-157 and TB-500 are independently verified to ≥98% purity with HPLC and mass spectrometry. You can order them as a coordinated wolverine stack or individually if you already have one compound in stock. Either way, a third-party Certificate of Analysis ships with every order.
A 15-amino acid pentadecapeptide fragment derived from human gastric juice protein BPC. Studied for angiogenesis via VEGFR2/Akt/eNOS, local tissue repair, nitric oxide modulation, tendon and ligament healing, gut mucosal repair, and neuroprotection. One of the most published peptides in preclinical recovery research — 100+ animal studies in the literature.
A synthetic analog of the naturally occurring Thymosin Beta-4 (Tβ4) protein. Studied for G-actin sequestration and actin polymerization regulation, systemic fibroblast and keratinocyte migration, muscle and connective tissue recovery, anti-inflammatory cytokine modulation, and cardiac tissue protection. Works systemically — the key complement to BPC-157's local action.
Both compounds are shipped lyophilized with individual batch-specific COA documentation. All VantyxLabs batches are traceable — if you need to verify a COA against a specific batch number, we have it on file.
| Compound | Purity | Molecular Weight | Primary Mechanism |
|---|---|---|---|
| BPC-157 | ≥98% | ~1,419 Da | Local angiogenesis, NO signaling, tissue repair |
| TB-500 | ≥98% | ~4,964 Da | Systemic actin regulation, cell migration, recovery |
The core scientific logic behind the wolverine stack is straightforward: BPC-157 and TB-500 don't compete with each other — they complement each other across two completely separate repair phases. Every researcher who has studied these compounds together has worked with the same fundamental insight.
BPC-157 is a synthetic 15-amino acid pentadecapeptide derived from human gastric juice. In preclinical models its most consistently documented mechanism is the promotion of angiogenesis — new blood vessel formation — via the VEGFR2/Akt/eNOS signaling pathway. This vascular network is the physical foundation of tissue repair: cells can't heal what they can't reach. BPC-157 builds that reach.
Beyond angiogenesis, BPC-157 upregulates growth factors including EGF and FGF, modulates nitric oxide production, and shows direct anti-inflammatory activity across multiple tissue types. Documented applications in preclinical research span tendons, ligaments, skeletal and smooth muscle, gut mucosa, bone, and peripheral nerves. The published research base is substantial — over 100 animal model studies are indexed on PubMed (NIH), making it one of the most studied repair peptides in the literature.
TB-500 is the synthetic equivalent of a naturally occurring fragment of Thymosin Beta-4, a protein that controls how cells move by regulating the availability of G-actin — the unpolymerized form of actin that drives cell locomotion. When TB-500 sequesters G-actin, fibroblasts, keratinocytes, and endothelial cells become more mobile and directionally migrate toward injury sites. This happens systemically — not just locally — which is the critical distinction from BPC-157's more site-specific action.
TB-500 also has independent angiogenic activity, anti-inflammatory properties via Thymosin Beta-4 pathway modulation, and has been studied specifically in cardiac muscle recovery models following ischemic injury. Research shows its activity across skeletal muscle, connective tissue, nerve fiber, and skin repair contexts. The primary scientific literature on Thymosin Beta-4 and synthetic analogs is indexed on PubMed.
BPC-157 creates the vascular infrastructure at the repair site — new blood vessels, growth factor signaling, local NO modulation. TB-500 mobilizes the repair cells from throughout the body and routes them to that infrastructure. Phase 1 and Phase 2 of the tissue repair cascade, handled by two non-redundant compounds. This is why the wolverine stack has become the standard dual-peptide recovery reference in preclinical research — and why neither compound alone produces the same research output as the combination.
The wolverine stack has documented preclinical research across a broader range of tissue types than almost any other peptide combination. Here's where the literature is strongest:
BPC-157 has one of the most robust preclinical records in tendon injury research. Studies in rat Achilles transection and rotator cuff models have documented accelerated tendon repair, improved tensile strength recovery, and reduced scar tissue formation in BPC-157 treated groups vs controls. TB-500's fibroblast migration effects deliver the primary collagen-producing cells directly to the injury site to reconstruct the extracellular matrix. Together the wolverine stack provides a dual-mechanism model for tendon research that single compounds simply cannot replicate.
TB-500 was originally characterized in the context of cardiac muscle — Thymosin Beta-4 was found to mobilize epicardial progenitor cells after ischemic injury in a landmark 2007 Nature study. Subsequent research extended this to skeletal muscle. Combined with BPC-157's angiogenic and anti-inflammatory effects in muscle tissue, the wolverine stack provides researchers with a dual-mechanism model for studying muscle injury, satellite cell behavior, and recovery timelines across both cardiac and skeletal contexts.
BPC-157 has documented neuroprotective activity in peripheral nerve injury models — promoting axon regrowth, reducing nerve fiber loss, and improving functional recovery scores in animal studies. TB-500 complements this with documented effects on neural cell migration and survival signaling. The wolverine stack provides researchers with a dual-mechanism peripheral nerve repair model that neither compound alone can deliver.
BPC-157 has a particularly strong research record in gastrointestinal tissue models. Studies have documented accelerated healing of gastric ulcers, intestinal anastomosis repair, and inflammatory bowel disease models in rodents. Its ability to upregulate growth factors and modulate the gut-brain axis makes it a versatile tool for GI research. TB-500's systemic cell migration activity extends this into broader mucosal and epithelial repair contexts.
Both wolverine stack compounds have independent anti-inflammatory research profiles that work through distinct pathways. BPC-157 modulates COX-2 expression, reduces inflammatory cytokines including TNF-alpha and IL-6, and counteracts oxidative stress. TB-500 downregulates pro-inflammatory mediators through Thymosin Beta-4 pathway signaling. Studying both together allows researchers to model coordinated multi-pathway inflammation resolution in injury models.
BPC-157 has published data in bone repair models — including fracture healing and osteoblast activity studies — where its angiogenic properties support the vascular supply needed for bone remodeling. Combined with TB-500's systemic fibroblast mobilization, the wolverine stack provides a useful model for studying coordinated soft tissue and bone repair in joint injury models where both hard and soft tissue components are involved.
Both BPC-157 and TB-500 follow the same reconstitution procedure. Proper handling preserves compound integrity throughout your research protocol.
| Step | Action | Notes |
|---|---|---|
| 1. Warm vial | Bring to room temperature before opening | Avoids condensation on lyophilized powder |
| 2. Add solvent | Bacteriostatic water or sterile PBS | Inject slowly along the vial wall |
| 3. Dissolve | Gently swirl — do not vortex | Clear, colorless solution = intact compound |
| 4. Aliquot | Divide into single-use research volumes | Minimizes freeze-thaw degradation |
| 5. Store | 4°C active; −20°C long-term stock | Use reconstituted within 28–30 days |
VantyxLabs ships the wolverine stack to researchers across Europe, Asia, Southeast Asia, the Middle East, and beyond. Here's who typically orders:
If you need bulk quantities or have institutional documentation requirements, message us directly on WhatsApp — we handle larger research orders regularly and can accommodate specific packaging or labeling needs.
Here's how the wolverine stack sits relative to related peptide research combinations:
| Stack | Compounds | Research Focus | Best For |
|---|---|---|---|
| Wolverine Stack | BPC-157 + TB-500 | Local + systemic tissue repair | Tendon, muscle, nerve, gut repair models |
| Glow Blend | BPC-157 + TB-500 + GHK-Cu | Repair + collagen + skin matrix | Multi-system + dermal regeneration |
| BPC-157 alone | BPC-157 | Local angiogenesis, gut repair | Single injury site or GI models |
| TB-500 alone | TB-500 | Systemic cell migration, recovery | Systemic repair, cardiac models |
BPC-157 + TB-500. ≥98% purity on both. COA included. Shipping worldwide from VantyxLabs.
Research use only. Not for human consumption. See full disclaimer.